Skip to main content

Page last checked

Symptom question · incretin class

Does GLP-1 medication cause hair loss?

None of the 36 compound guides checked lists hair loss as a reported side effect. 25 have published safety information that does not mention it. BPC-157, TB-500, GHK-Cu, MOTS-c, Epitalon, Kisspeptin-10, IGF-1 LR3, PEG-MGF, KPV, Selank and AHK-Cu have no published human safety data.

Source: checked against 36 compound guides; rates are shown exactly as reportedFDA label

That describes these sources, not the compounds themselves. A gap can mean nobody saw the effect, nobody tied it to treatment, or the source reported it elsewhere. Those are different situations. A reaction table cannot tell them apart.

The searches behind this question name brands: Ozempic, Wegovy, Mounjaro, Zepbound. The reaction record belongs to the drug underneath each of them — semaglutide for the first two, tirzepatide for the second two. Both molecules are in the table below.

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Information checked 2026-08-20

At a glance

Compounds that list it

0 of 36

Only in a combined category

0

No published human safety data

11

Best available source

FDA label

Which compounds list hair loss

None of the labels or studies checked lists hair loss as a reported side effect. The table keeps that result blank instead of turning stories or assumptions into a percentage.

◆ Hair loss across 36 compoundssource shown for every row
Every compound covered on this site, showing whether it lists hair loss and at what frequency its own cited source states.
CompoundHow it appearsFrequency reportedSource type
TirzepatideZepbound, MounjaroNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaglutideWegovy, Ozempic, RybelsusNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
LiraglutideVictoza, SaxendaNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
RetatrutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
CagrilintideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
SurvodutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
BPC-157No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
TesamorelinEgrifta SV, Egrifta WRNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
PT-141VyleesiNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
CJC-1295Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IpamorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
TB-500No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
GHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
SermorelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MOTS-cNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
AOD-9604Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
NAD+Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
EpitalonNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Kisspeptin-10No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
DSIPNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
HexarelinNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
IGF-1 LR3No published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
PEG-MGFNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
LL-37Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
KPVNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Thymosin alpha-1Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SS-31ForzinityNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—FDA label
SemaxNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
SelankNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
Melanotan IINot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
MazdutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PinealonNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—limited human data
AHK-CuNo published human safety dataNo human trial has published enough safety data to list reactions for this compound.—no human dose shown to work
VK2735Not listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
ZenagamtideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial
PemvidutideNot listed in the source checkedThe label or study checked for this compound does not list this reaction.—Human trial

A blank result means the label or study checked here does not list the reaction. It does not prove the reaction cannot happen, and it does not replace the full prescribing information. A pharmacist or clinician can review the complete label alongside the rest of a person’s medicines.

What people reported to the FDA

The first table summarizes labels and published trials. This table shows reports filed with the FDA after the medicines went on sale. Each percentage is the share of reports for that product that mention this symptom—not the share of patients who experienced it.

Each GLP-1 brand in the FDA snapshot, and what share of its reports names this symptom.
ProductShare of its own reportsAll reports
Ozempicsemaglutidebelow 2.3% of Ozempic reports66,161 reports
Zepboundtirzepatide2.3% of Zepbound reports70,141 reports
Trulicitydulaglutidebelow 2.1% of Trulicity reports88,332 reports
Rybelsussemaglutidebelow 2.1% of Rybelsus reports7,379 reports
Wegovysemaglutidebelow 2.0% of Wegovy reports21,044 reports
Saxendaliraglutidebelow 1.9% of Saxenda reports10,040 reports
Mounjarotirzepatidebelow 1.7% of Mounjaro reports93,975 reports
Victozaliraglutidebelow 1.7% of Victoza reports44,086 reports

A row reading “below” is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All that can be proved is that it sits under the 25th. Read from FDA on 2026-08-17.

Reports are not rates and a report is not proof the drug did it. How to read this data, and the questions it answers on its own.

3Read deeperWhy it happens, when it appears, and what the page proves

Why the question arises at all

Hair grows on a cycle. Each follicle spends a long stretch growing and a short stretch at rest before the hair sheds. Shedding that shows up weeks or months after a physical stress is a recognized pattern in general medicine. The stress can be a big, fast change in body weight, an illness, surgery, or a sharp change in what someone eats. The pattern is about the stress, not about any particular cause of it.

That is why people ask about hair loss after fast weight loss, however the weight came off. But none of the studies in this comparison measured whether that explains one person’s shedding.

This is general physiology, not a measured result for these compounds. It explains why the question is reasonable without inventing a rate.

What it would take to answer this properly

A publishable answer would need a defined group, an untreated comparison group, a set way to measure shedding, and enough follow-up time. Those features separate a reaction rate from an impression. They also explain why a weight-loss trial cannot be read as a hair-loss study.

Reports gathered outside such a structure are real experiences and they are not nothing — but they cannot be counted. There is no denominator. People who did not experience it never post, so what you can see is skewed from the start. No amount of it adds up to a rate.

No cited study has published a measurement. If that changes, the result should be shown with its sample size, comparison group and citation rather than replaced with an estimate.

Four readings of the same absence

An empty cell invites interpretation, and most of the interpretations in circulation run in whichever direction the writer already favored. Each row below is a claim that gets made in both directions from the same non-result.

The claimWhat the evidence shows
These compounds do not cause hair loss.Not supported. Nothing here looked for it and reported a null result. A gap in a reaction table is not a measured finding of no effect. Citing it as one is the same mistake as citing it the other way.
These compounds cause hair loss.Not supported by these labels or trials. None lists hair loss or gives a rate for it.
The label would say so if it happened.Overstated. A label lists what trials recorded and what later monitoring pinned on the drug. Effects that arrive late, or that get put down to weight change rather than to the drug, are the hardest kind to capture that way.
It is caused by the weight loss, not the medicine.Plausible and unestablished. It is the general pattern the section above describes. Separating a consequence of fast weight change from an effect of the drug causing it needs a study design nobody cited here used.

Taking this to a clinician

Shedding has a long list of causes that have nothing to do with these compounds. Thyroid problems and iron levels are among the ones usually checked first. Several of them can be found and treated.

ClinicianA clinician can look for another cause and review the full medicine list. Do not start, stop or change treatment because of a search result.

Common questions

Is hair loss listed as a side effect of Ozempic or Wegovy?

Not in the semaglutide side-effect summary used for both brand names.

That summary is an extract, not the full prescribing label. A pharmacist or clinician can check the complete label for a specific product.

Is it the medication or the weight loss?

The cited sources cannot separate the two causes.

Hair shedding can follow rapid weight change. Separating that from a direct drug effect would require a trial designed for the question, and none of these trials was.

How long does it last, and does hair grow back?

No label or trial in this comparison reports a duration or recovery rate.

That is a real limit rather than an evasion. What happens next depends on the cause, and finding the cause is a clinical assessment rather than a search result. That is why this question routes to a clinician.

Do the different GLP-1 compounds differ on this?

The available labels and trials do not support a ranking because none reports hair loss as a measured side effect.

A comparison needs two measurements. With none, any claim that one compound is gentler on hair than another has no source underneath it. Confidence in the phrasing does not change that.

Would supplements or a higher protein intake prevent it?

No cited trial evaluates a treatment or supplement for this purpose, so none is recommended.

Several labels list decreased appetite as a side effect. Eating less can make it harder to get enough protein and other nutrients, but the right plan depends on the person. A clinician or dietitian can help set one.

Why do so many pages give a percentage for this?

Because a number performs better than an absence, and nothing stops a page from printing one.

Figures in this area are usually lifted from a study of different people, a different treatment or a different question. They then get repeated without the qualifier that made them mean anything. This site’s build gate blocks any clinical value with no citation attached. That is why this page has an empty table rather than a plausible one.

Is muscle loss a different question from this one?

Yes, and the reason the two absences are different is worth stating.

A side-effect table is designed to capture hair loss, and these sources do not list it. Lean mass is not a side effect. It is a body-composition measurement, taken with different instruments for a different purpose. It would not appear in that table even if someone had measured it. That distinction is set out on the muscle-loss page in this section.

Want the full picture for one compound? Open its guide for uses, dosage information, side effects and serious warnings.

Every tirzepatide reaction, not only hair loss

9 common and 6 serious tirzepatide reactions, in full past hair loss.

The full semaglutide profile behind its hair loss entry

Frequencies as the semaglutide source states them, read directly rather than via hair loss.

The constipation question, alongside hair loss

One reaction, constipation, read down every page instead of out of hair loss alone.

The nausea question, alongside hair loss

One reaction, nausea, read down every page instead of out of hair loss alone.

The pages each hair loss row is read from

See the strongest source available for every compound, with hair loss as context

How long hair loss lasts, and why nobody says

No source cited on this site states how long any of these reactions lasts, with hair loss as one example

From a hair loss page to an exact syringe draw

Concentration, units per draw and draws per vial, including Hair loss

All the cross-compound reads, including hair loss

Which sources list a reaction, under what name and how often, including hair loss

Tirzepatide beyond its hair loss listing

An approved tirzepatide label exists — beyond hair loss.

Every symptom in this section is listed on the symptom questions index.

42primary sources, each with the day we read it — open the documents used on this page